NASDAQ:OBSV ObsEva (OBSV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About ObsEva Stock (NASDAQ:OBSV) Get ObsEva alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume125 shsAverage Volume8.94 million shsMarket Capitalization$7.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ObsEva SA was a biopharmaceutical company focused on developing and commercializing therapies for women’s health conditions. The company’s research programs addressed reproductive and gynecological disorders, including uterine fibroids and endometriosis. Its leading product candidate was linzagolix, an oral gonadotropin-releasing hormone antagonist designed to reduce symptoms associated with hormone-dependent conditions. Linzagolix was approved in the European Union and the United Kingdom under the brand name Yselty for the treatment of uterine fibroids, with additional development and commercialization efforts directed toward endometriosis. ObsEva pursued partnerships to support the product’s commercialization in international markets. ObsEva was founded in 2015 and was headquartered in Geneva, Switzerland. Ernest Loumaye, a physician and biotechnology executive, was a co-founder and served as chief executive officer during much of the company’s development. ObsEva later entered insolvency proceedings, and its Nasdaq-listed securities were delisted, so the company’s public-market status is primarily historical.AI Generated. May Contain Errors. Read More Receive OBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OBSV Stock News HeadlinesObsEva SA OBSNNovember 11, 2023 | morningstar.comMObsEva SA OBSEFNovember 11, 2023 | morningstar.comMWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers. Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever. Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7. | Porter & Company (Ad)ObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comObsEva Files Year End 2022 Financial StatementsMarch 31, 2023 | finance.yahoo.comObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023March 15, 2023 | finance.yahoo.comObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim ChairmanMarch 13, 2023 | markets.businessinsider.comObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandMarch 13, 2023 | finance.yahoo.comSee More Headlines OBSV Stock Analysis - Frequently Asked Questions How were ObsEva's earnings last quarter? ObsEva SA (NASDAQ:OBSV) released its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.23. When did ObsEva IPO? ObsEva (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO. What other stocks do shareholders of ObsEva own? Based on aggregate information from My MarketBeat watchlists, some other companies that ObsEva investors own include NIO (NIO), Bionano Genomics (BNGO), SNDL (SNDL), Inovio Pharmaceuticals (INO), Plug Power (PLUG), Alibaba Group (BABA) and FuelCell Energy (FCEL). Company Calendar Last Earnings11/04/2021Today10/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OBSV CIK1685316 Webwww.obseva.com Phone(122) 552-3840FaxN/AEmployees50Year Founded2012Profitability EPS (Trailing Twelve Months)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-416.36% Return on Assets-92.01% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / BookN/AMiscellaneous Outstanding Shares77,971,000Free Float66,743,000Market Cap$7.94 million OptionableNot Optionable Beta0.68 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:OBSV) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYesterday's deadline changed everythingIn June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times th...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
